Related Experiment Videos
Allogeneic stem cell transplantation for Evans syndrome.
Y Oyama1, E B Papadopoulos, M Miranda
1Division of Immune Therapy and Autoimmune Diseases, Northwestern University Medical Center, Chicago, IL, USA.
Bone Marrow Transplantation
|January 10, 2002
Summary
Allogeneic hematopoietic stem cell transplant (HSCT) offers a potential cure for rare Evans syndrome, a condition combining autoimmune thrombocytopenia and hemolytic anemia. This treatment led to long-term remission in a refractory patient, despite potential toxicities.
Area of Science:
- Hematology
- Immunology
- Transplantation
Background:
- Evans syndrome is a rare autoimmune disorder involving concurrent immune thrombocytopenia and immune hemolytic anemia.
- Standard treatments include corticosteroids, splenectomy, and immunosuppressants, often with limited success in refractory cases.
Observation:
- A patient with refractory Evans syndrome underwent allogeneic hematopoietic stem cell transplant (HSCT).
Findings:
- The patient achieved complete clinical and serologic remission lasting over 30 months post-HSCT.
- Allogeneic HSCT demonstrated curative potential for Evans syndrome.
Implications:
- Allogeneic HSCT represents a potentially curative option for refractory Evans syndrome.
- Significant toxicities associated with HSCT must be carefully considered.